Elyse Abramson

Talphera, formerly known as AcelRx Pharmaceuticals, is a Hayward-based company focused on developing and commercializing innovative therapies for use in medically supervised settings. Their mission is to deliver advances in care to patients by providing healthcare providers with high-quality products that offer improved cost and convenience. With their lead candidate, Niyad nafamostat mesylate, they aim to become the first FDA-approved regional anticoagulant for use in the extracorporeal circuit, potentially improving the standard of care for patients undergoing renal replacement therapy. Talphera's pipeline includes various product candidates, such as Niyad for anticoagulation of the extracorporeal circuit, LTX-608 for various indications, and pre-filled syringe product candidates like Fedsyra Ephedrine and PFS-02 Phenylephrine. With a strong focus on research and development, Talphera is committed to advancing care and delivering innovative solutions to medically supervised settings.Generated from the website